1-3 of 3
Stephen C.L. Gough
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data

John M. Dennis, William E. Henley, Michael N. Weedon, Mike Lonergan, Lauren R. Rodgers, Angus G. Jones, William T. Hamilton, Naveed Sattar, Salim Janmohamed, Rury R. Holman, Ewan R. Pearson, Beverley M. Shields, Andrew T. Hattersley, MASTERMIND Consortium, Catherine Angwin, Kennedy J. Cruickshank, Andrew J. Farmer, Stephen C.L. Gough, Alastair M. Gray, Christopher Hyde, Christopher Jennison, Mark Walker
Journal: Diabetes Care
Diabetes Care 2018;41(9):1844–1853
https://doi.org/10.2337/dc18-0344
Published: 02 August 2018
View article titled, Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data
Open the PDF for Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data in another window
Includes: Supplementary data
Journal Articles

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial

Stephen C.L. Gough, MD, Anuj Bhargava, MD, Rajeev Jain, MD, Henriette Mersebach, MD, Søren Rasmussen, PHD, Richard M. Bergenstal, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2536–2542
https://doi.org/10.2337/dc12-2329
Published: 13 August 2013
View article titled, Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: <subtitle>A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial</subtitle>
Open the PDF for Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes: <subtitle>A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial</subtitle> in another window
Includes: Supplementary data
Journal Articles

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

Luigi Meneghini, MD, Stephen L. Atkin, MD, Stephen C.L. Gough, MD, Itamar Raz, MD, Lawrence Blonde, MD, Marina Shestakova, MD, Stephen Bain, MD, Thue Johansen, MD, Kamilla Begtrup, MSC, Kåre I. Birkeland, MD, on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(4):858–864
https://doi.org/10.2337/dc12-1668
Published: 14 March 2013
View article titled, The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: <subtitle>A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes</subtitle>
Open the PDF for The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: <subtitle>A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes</subtitle> in another window
Includes: Supplementary data